Oral non-cephalosporin formulations facility (Emerging markets)

Orchid's oral non-cephalosporin formulations facility specialises in the manufacture of Nutraceutical products. The facility produces a range of dietary supplements for the advanced markets.

Many other high-value products like anti-diabetics, cardiovascular drugs (CVS), anti-depresents and anti-epileptics are manufactured in this facility to cater to the emerging markets.

Built to GMP standards (WHO guidelines), this facility has the capacity to manufacture 228 million tablets and 30 million capsules per annum.

The plant is remarkable for its high technology air handling systems, which ensure very low humidity conditions. The facility has state-of-the-art packaging machinery and a full-spectrum, dedicated quality control and microbiological services, adding distinctiveness to the manufacturing quality.

Designed for optimal operating conditions and uni-directional flow of resources and materials, the facility is approved by the Australian-TGA and is being offered for inspection by several other leading international regulatory agencies.

Oral cephalosporin formulations facility (Emerging Markets)

Orchid's oral cephalosporin formulations facility manufactures cephalosporin oral products dedicated to the domestic and emerging markets.

The facility has the capability to manufacture different dosage forms like tablets, capsules, dry syrups and liquid orals.

The facility conforms to cGMP standards and is approved by the WHO. The facility is being offered for approvals by leading regulatory agencies.